Evolus, Inc. raised earnings guidance for the full year 2023. For the year, the company now expects total net revenues to be between $194 million and $198 million from $185 Million to $195 Million, representing year-over-year growth of greater than 30% and magnitudes above the estimated growth rate of the aesthetic neurotoxin market.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.76 USD | -0.12% | -4.84% | +21.27% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.27% | 800M | |
+30.73% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+14.72% | 239B | |
+9.86% | 210B | |
-7.40% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Raises Earnings Guidance for the Full Year 2023